<DOC>
	<DOCNO>NCT01492985</DOCNO>
	<brief_summary>The combination GTU-MultiHIV B DNA LIPO-5 vaccine prime-boost strategy expect induce strong diverse HIV-specific immune response HIV-infected patient . The investigator carry clinical therapeutic immunization `` proof concept '' trial HIV infect patient . The investigator propose multi-center double blind randomize versus placebo phase II clinical trial patient chronic asymptomatic HIV-infected patient , undetectable viral load treat potent combination antiviral drug . Patients continue antiviral therapy combine either therapeutic vaccination placebo vaccination . Patients undergo procedure include prime GTU-MultiHIV B DNA vaccine placebo administer IM injection via Biojector ( needle-free injection system ) follow boost LIPO-5 vaccine placebo also give IM . In total , 105 HIV-1 patient enrol : 35 placebo arm 70 vaccine arm . Patients receive antiretroviral treatment 3 administration DNA vaccine placebo week 0 , 4 12 ( correspond prime vaccination ) . They also receive 2 dos LIPO-5 vaccine placebo week 20 24 ( correspond boost vaccination ) . At week 36 antiretroviral treatment interrupt week 48 . Patients intensely monitor treatment interruption period . After start cART treatment ( late W48 ) , data collection clinical car carry . A blood sample W74 allow study persistence ot immunize response , 1 year injection last vaccine/placebo . The primary efficacy endpoint plasma HIV-1 RNA level week 48 ( e.g . 12 week stop antiviral treatment ) . The main hypothesis conduct phase II randomize trial immune response vaccinate patient may associate good control viral replication follow c-ART interruption compare placebo-vaccinated patient .</brief_summary>
	<brief_title>Lipopeptide Immunisation With GTU-multiHIV Trial</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : Documented HIV1 infection ( ELISA Western blot ) Age ≥ 18 year &lt; 60 year No history CDC category C clinical event ( 1993 ) , include cutaneous Kaposi 's sarcoma CD4 Nadir ≥ 300/mm3 Under antiretroviral treatment CD4 ≥ 600/mm3 measurement within previous 6 months* prior W3 screen visit ( one single CD4 value 550600 cells/ mm3 permit ) CD4 value ≥ 600/ mm3 W3 screen visit Plasma HIV1RNA &lt; 50 copies/mL measurement within previous 6 months* ( An occasional measurement HIV1 RNA ( socalled `` blip `` 50 200 copies/mL permit ) HIV1RNA &lt; 50 copies/mL W3 screen visit * In absence measurement last 6 month , measurement perform last 12 month accept Treatment combination antiviral drug ( cART ) least 18 month regardless combination , condition : W24 visit nonnucleoside inhibitor replace protease inhibitor potentiate ritonavir failure resistance protease inhibitor previously report With adequate method contraception negative pregnancy test ( βHCG plasma ) woman childbearing potential Laboratory parameter W3 : polynuclear neutrophil ≥ 1,000/mm3 haemoglobin ≥ 10 g/dl platelet ≥ 100,000/mm3 creatinine ≤ 1.5 x N AST , ALT , bilirubin ≤ 2.5 x N proteinuria ≤ 1 g/L ( ++ ) antinuclear antibody ≤ 1/320 anticardiolipin antibody ≤ 30 U lupus anticoagulant Participant agreeing treat follow least 74 week accord protocol Participant agree interrupt his/her cART treatment , applicable , replace nonnucleoside inhibitor protease inhibitor potentiate ritonavir W24 Participant agree use condom , particular ART interruption period ( visit S36 visite S48 ) Participant cover HealthInsurance ( article L112111 Code de la Santé Publique ) Written inform consent ( late day preinclusion exams do context trial ) ( article L112211 Code de la Santé Publique ) . Exclusion criterion Pregnancy lactation , HIV2 infection ( isolate associate HIV1 ) , History ( experimental ) vaccination HIV , Treatment chemotherapy interferon alpha ( IFNα2b ) , sargramostim ( GMCSF ) , IL2 IL7 ongoing previous12 week inclusion ( W0 ) , Treatment corticoid immunosuppressive agent ongoing previous12 week inclusion trial ( W0 ) , Administration live vaccine within 60 day prior inclusion trial ( W0 ) inactivate vaccine within 14 day W0 visit Planned administration , followup participant , vaccine recommend France part usual care patient History cancer ( except basal cellular skin carcinoma ) , History cardiovascular disease ( angina , myocardial infarction , transient ischemic attack , stroke ) , History renal failure relate HIV , History thrombocytopenia relate HIV ( &lt; 50,000/mm3 ) , Ongoing cardiac , pulmonary , thyroid , renal neurological ( peripheral central ) disease , Progressive infection , Coinfection hepatitis B ( HBsAg + isolate antiHBc antibody + ) hepatitis C ( antiHCV antibody PCR + ) , Known allergy aminoglycosides , Person place juridical protection ( article L11222 Code de la Santé Publique ) Person participate another biomedical research exclusion period always ongoing screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>